Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Inclusion Criteria: * Male or female subjects 18 years or older * Histologically proven diagnosis of follicular non-Hodgkin's lymphoma grades 1or 2 according to the World Health Organization classification * Subjects must have received at least 12 doses (375mg/m2 or appropriately adjusted dose) of rituximab for the treatment of this lymphoma as single agent rituximab or in rituximab-containing regimens as documented in the subject's medical record * Documented relapse or progression following last antineoplastic treatment * At least 1 measurable tumor mass (≥1.5 cm x ≥1.0 cm) Exclusion Criteria: * Subjects with histological or clinical transformation to an aggressive lymphoma * prior treatment with VELCADE or fludarabine. * antineoplastic (including unconjugated therapeutic antibodies), experimental, or radiation therapy within 3 weeks before randomization * nitrosoureas within 6 weeks before randomization * radioimmunoconjugates or toxin immunoconjugates within 10 weeks before randomization * major surgery within 3 weeks before randomization * chronic use of corticosteroids, such as dexamethasone